BIOBRIEF
ABCL635 is an antibody targeting the same receptor as Astellas's Veozah and Bayer's Lynkuet, and the cross trial gap is real, but the readout covers 92 patients over four weeks.
In a 92-patient Phase 2 trial, AbCellera's ABCL635 cut moderate-to-severe hot flashes by 8.8 per day at Week 4 versus 3.5 on placebo, a 5.3 placebo-adjusted gap that, on cross-trial terms, runs roughly double the 2.1 to 3.29 range posted by the two approved non-hormonal pills. ABCL635 is an antibody against the same target both incumbents hit with small-molecule pills.
The target is the neurokinin 3 receptor, NK3R. Astellas's Veozah and Bayer's Lynkuet both block it and are FDA-approved for moderate-to-severe menopausal vasomotor symptoms. Mean severity on ABCL635 also fell 1.4 points at Week 4 versus 0.3 on placebo, a second endpoint that favored the drug. Patients averaged roughly ten moderate-to-severe hot flashes per day at baseline.
On a Monday investor call, CEO Carl Hansen called ABCL635 "a potential best-in-class non-hormonal therapy" and "a highly de-risked program." BMO Capital Markets analysts said the data "firmly validate ABCL635 as a potentially best-in-class treatment."
The cross-trial gap is real but early. Patients in each study had different baselines, doses, and protocols; the comparator numbers come from the incumbents' own FDA filings, not a head-to-head study. The Phase 2 readout covers four weeks of treatment, and pivotal studies, regulatory review, and commercial launch still stand between ABCL635 and any patient.